PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.79%
Cash & equivalents declining -9.79% while AGEN's grows 44.17%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Below half of AGEN's 44.17%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.77%
Below half of AGEN's 19.75%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-10.21%
≥ 1.5x AGEN's -4.21%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.10%
≥ 1.5x AGEN's -2.46%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
Below half of AGEN's 10.06%. Michael Burry sees a potential red flag for stagnation or capital shortage.
3.20%
Less than half of AGEN's -0.75%. David Dodd sees a more disciplined AP approach or lower volume.
-75.32%
Above 1.5x AGEN's -22.85%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
-4.13%
Below half of AGEN's 7.45%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
0.52%
Less than half of AGEN's 3.25%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.45%
Above 1.5x AGEN's -2.07%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-1.62%
Above 1.5x AGEN's -0.23%. Michael Burry sees a potential leverage warning sign.
7.69%
50-75% of AGEN's 10.39%. Bruce Berkowitz notes minimal new equity relative to competitor.
-2.53%
0.5-0.75x AGEN's -3.71%. Martin Whitman is wary of weaker retention or lower profitability.
-4.62%
Less than half of AGEN's 234.15%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-10.53%
Below half AGEN's 9.21%. Michael Burry sees potential underperformance in building shareholder capital.
-9.71%
Below half AGEN's 10.06%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-19.69%
Above 1.5x AGEN's -1.55%. Michael Burry sees a major jump. Investigate leverage rationale.
9.58%
Less than half of AGEN's -84.97%. David Dodd sees better deleveraging or stronger cash buildup than competitor.